跳到正文
原文
NEJM· Jiayu Wang Huiping Li Fei Xu Tao Wu Zhongsheng Tong Jiuwei Cui Xujuan Wang Zhenchuan Song Tao Sun Huihui Li Weimin Xie Jing Sun Xueying Zhang Yuee Teng Xiaoping Li Jinhai Zhu Ting Luo Bing Zhao Fangling Ning Chunwei Xie Lu Gan Guobing Yin Yang Li Chunxiu Yuan Wei You Zhiyong Wu Qiang Liu Xiangshun Kong Jianying Chang Jiuda Zhao Zhenhua Zhai Quchang Ouyang Xinghua Han Fanfan Li Jianyun Nie Guohui Han Chongsheng Xia Wei Huang Silong Xiang Kai Zou Yulei Wang and Binghe Xu·· 24 天前精选AI 评分62

Anbenitamab联合HB1801治疗HER2阳性晚期乳腺癌的NEJM研究

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer

AI 导读

NEJM在线发表一项研究,评估Anbenitamab联合HB1801用于HER2阳性晚期乳腺癌。目前仅有标题与作者信息,具体疗效与安全性数据尚未披露。

来源:NEJM · nejm.org